Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines

Robert J. Morgan; Ronald D. Alvarez; Deborah K. Armstrong; Robert A. Burger; Lee May Chen; Larry Copeland; Marta Ann Crispens; David M. Gershenson; Heidi J. Gray; Ardeshir Hakam; Laura J. Havrilesky; Carolyn Johnston; Shashikant Lele; Lainie Martin; Ursula A. Matulonis; David M. O'Malley; Richard T. Penson; Matthew A. Powell; Steven W. Remmenga; Paul Sabbatini; Joseph T. Santoso; Julian C. Schink; Nelson Teng; Theresa L. Werner; Mary A. Dwyer; Miranda Hughes

doi:10.6004/jnccn.2013.0142

Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee May Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul SabbatiniJoseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, Miranda Hughes

Research output: Contribution to journal › Article › peer-review

102 Scopus citations

Abstract

These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.

Original language	English (US)
Pages (from-to)	1199-1209
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	11
Issue number	10
DOIs	https://doi.org/10.6004/jnccn.2013.0142
State	Published - Oct 1 2013
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2013.0142

Cite this

Morgan, R. J., Alvarez, R. D., Armstrong, D. K., Burger, R. A., Chen, L. M., Copeland, L., Crispens, M. A., Gershenson, D. M., Gray, H. J., Hakam, A., Havrilesky, L. J., Johnston, C., Lele, S., Martin, L., Matulonis, U. A., O'Malley, D. M., Penson, R. T., Powell, M. A., Remmenga, S. W., ... Hughes, M. (2013). Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 11(10), 1199-1209. https://doi.org/10.6004/jnccn.2013.0142

Morgan, RJ, Alvarez, RD, Armstrong, DK, Burger, RA, Chen, LM, Copeland, L, Crispens, MA, Gershenson, DM, Gray, HJ, Hakam, A, Havrilesky, LJ, Johnston, C, Lele, S, Martin, L, Matulonis, UA, O'Malley, DM, Penson, RT, Powell, MA, Remmenga, SW, Sabbatini, P, Santoso, JT, Schink, JC, Teng, N, Werner, TL, Dwyer, MA & Hughes, M 2013, 'Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 10, pp. 1199-1209. https://doi.org/10.6004/jnccn.2013.0142

@article{70a4e8ae739048efa727c83e7151f701,

title = "Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines",

abstract = "These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.",

author = "Morgan, {Robert J.} and Alvarez, {Ronald D.} and Armstrong, {Deborah K.} and Burger, {Robert A.} and Chen, {Lee May} and Larry Copeland and Crispens, {Marta Ann} and Gershenson, {David M.} and Gray, {Heidi J.} and Ardeshir Hakam and Havrilesky, {Laura J.} and Carolyn Johnston and Shashikant Lele and Lainie Martin and Matulonis, {Ursula A.} and O'Malley, {David M.} and Penson, {Richard T.} and Powell, {Matthew A.} and Remmenga, {Steven W.} and Paul Sabbatini and Santoso, {Joseph T.} and Schink, {Julian C.} and Nelson Teng and Werner, {Theresa L.} and Dwyer, {Mary A.} and Miranda Hughes",

year = "2013",

month = oct,

day = "1",

doi = "10.6004/jnccn.2013.0142",

language = "English (US)",

volume = "11",

pages = "1199--1209",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "10",

}

TY - JOUR

T1 - Ovarian cancer, version 2.2013

T2 - Featured updates to the NCCN guidelines

AU - Morgan, Robert J.

AU - Alvarez, Ronald D.

AU - Armstrong, Deborah K.

AU - Burger, Robert A.

AU - Chen, Lee May

AU - Copeland, Larry

AU - Crispens, Marta Ann

AU - Gershenson, David M.

AU - Gray, Heidi J.

AU - Hakam, Ardeshir

AU - Havrilesky, Laura J.

AU - Johnston, Carolyn

AU - Lele, Shashikant

AU - Martin, Lainie

AU - Matulonis, Ursula A.

AU - O'Malley, David M.

AU - Penson, Richard T.

AU - Powell, Matthew A.

AU - Remmenga, Steven W.

AU - Sabbatini, Paul

AU - Santoso, Joseph T.

AU - Schink, Julian C.

AU - Teng, Nelson

AU - Werner, Theresa L.

AU - Dwyer, Mary A.

AU - Hughes, Miranda

PY - 2013/10/1

Y1 - 2013/10/1

N2 - These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.

AB - These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.

UR - http://www.scopus.com/inward/record.url?scp=84887254206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887254206&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2013.0142

DO - 10.6004/jnccn.2013.0142

M3 - Article

C2 - 24142821

AN - SCOPUS:84887254206

SN - 1540-1405

VL - 11

SP - 1199

EP - 1209

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 10

ER -

Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this